Payment overview · 2025
General Payments
$1,157.59
61 reported records · 15 companies
Healthcare provider profile · identity verified
Robert Van Clampitt, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MARION, VA · NPI 1225090509
Verified facts
What the public records show
CMS Open Payments records show Robert Van Clampitt, M.D. received $1,157.59 in general payments during 2025 across 61 reported records.
GlaxoSmithKline, LLC. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rexulti, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $207.35 | 17.9% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.78 | 17.7% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $172.65 | 14.9% | 10 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $114.08 | 9.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.61 | 7.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $71.25 | 6.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.72 | 5.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.69 | 3.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.10 | 3.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.03 | 3.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.06 | 2.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.13 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.51 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.23 | 1.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,157.59 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $239.37 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $207.35 | 13 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $114.08 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.94 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $71.25 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 89 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
89 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 26 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
89 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 949 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 689 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 544 | 68 |
| Furosemide | Furosemide | 542 | 76 |
| Potassium Chloride | Potassium Chloride | 524 | 54 |
| Lisinopril | Lisinopril | 507 | 81 |
| Omeprazole | Omeprazole | 496 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 63 |
| Famotidine | Famotidine | 408 | 24 |
| Montelukast Sodium | Montelukast Sodium | 407 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 392 | 43 |
| Simvastatin | Simvastatin | 384 | 37 |
| Sertraline Hcl | Sertraline Hcl | 382 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 84 |
| Metformin Hcl | Metformin Hcl | 364 | 67 |
| Eliquis | Apixaban | 360 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 347 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 340 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 275 | 47 |
| Trazodone Hcl | Trazodone Hcl | 268 | 40 |
| Alprazolam | Alprazolam | 247 | 28 |
| Lorazepam | Lorazepam | 231 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 218 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 217 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 35 |
| Allopurinol | Allopurinol | 201 | 30 |
| Meloxicam | Meloxicam | 186 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 28 |
| Glipizide | Glipizide | 176 | 38 |
| Valsartan | Valsartan | 176 | 16 |
| Donepezil Hcl | Donepezil Hcl | 175 | 15 |
| Gabapentin | Gabapentin | 167 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 46 |
| Prednisone | Prednisone | 163 | 31 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 156 | 17 |
| Pregabalin | Pregabalin | 143 | 18 |
| Ozempic | Semaglutide | 140 | 26 |
| Diazepam | Diazepam | 137 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 136 | suppressed |
| Losartan Potassium | Losartan Potassium | 130 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 33 |
| Dilt-Xr | Diltiazem Hcl | 124 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 27 |
| Xarelto | Rivaroxaban | 123 | 16 |
| Sucralfate | Sucralfate | 120 | 15 |
| Carvedilol | Carvedilol | 113 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 31 |
| Torsemide | Torsemide | 103 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 103 | 26 |
| Bupropion Xl | Bupropion Hcl | 102 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 24 |
| Cefdinir | Cefdinir | 97 | 70 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 95 | 21 |
| Entresto | Sacubitril/Valsartan | 90 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 58 |
| Rexulti | Brexpiprazole | 89 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 88 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 78 | 17 |
| Fluconazole | Fluconazole | 76 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 21 |
| Azithromycin | Azithromycin | 66 | 47 |
| Mirtazapine | Mirtazapine | 66 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 64 | 12 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 63 | suppressed |
| Acyclovir | Acyclovir | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 60 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Cilostazol | Cilostazol | 58 | 12 |
| Digoxin | Digoxin | 58 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 12 |
| Ondansetron Odt | Ondansetron | 58 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 27 |
| Mupirocin | Mupirocin | 55 | 33 |
| Finasteride | Finasteride | 54 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 52 | suppressed |
| Lansoprazole | Lansoprazole | 51 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 36 |
| Dapsone | Dapsone | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 47 | 30 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Atenolol | Atenolol | 46 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | 11 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 18 |
| Risperidone | Risperidone | 43 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 25 |
| Celecoxib | Celecoxib | 40 | suppressed |
| Enulose | Lactulose | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 34 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 23 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | suppressed |
| Otezla | Apremilast | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 25 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 11 |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Nystop | Nystatin | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Probenecid | Probenecid | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,157.59 · 61 records | GlaxoSmithKline, LLC. | AIRSUPRA, BREZTRI, CAPLYTA, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, HETLIOZ, JARDIANCE, Ohtuvayre, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, WATCHMAN Access System, Wegovy, XIFAXAN | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error